Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

872272

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134186
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134187 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872273

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Acute Lymphoblastic Leukaemia: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134187
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>- Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>- Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine for treating ALL after two therapies.</p><p> </p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 134186 question first answered 03/04/2018 13:25:08 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872274

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer and Rare Diseases: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NICE appraisals for new treatments for rare (a) diseases and (b) cancers.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134188
answer	answer is ministerial correction date of answer 03/04/2018 answer text <p>Most new drugs and significant licence indications are assessed by the National Institute for Health and Care Excellence (NICE) through its technology appraisal programme, through which NICE has been able to recommend a significant number of drugs for the treatment of rare cancers and other diseases for routine use on the National Health Service. NICE also operates a separate Highly Specialised Technology evaluation programme for the evaluation of a very small number of treatments for very rare diseases.</p><p>The methods and processes NICE uses in the development of its guidance are internationally respected, have been developed through extensive engagement with a full range of stakeholders, including the Department, and are regularly reviewed to ensure that they remain fit for purpose.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/04/2018 13:25:57 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872275

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134189
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:02:10 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872373

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what drugs have been funded through the Cancer Drugs Fund this year; and how much funding remains in that Fund.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134287
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Since April 2017, there are currently 27 drugs in 42 indications that are funded by the Cancer Drugs Fund (CDF). A full list of current and previous CDF drugs can be viewed at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/" target="_blank">https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/</a></p><p> </p><p>The latest published spend for the first six months of 2017/18 implies a circa £76 million of unused funding for that period against the CDF. The quarterly activity report is a snapshot of CDF spend at a point in time and the spend figure will increase as more drugs are added to the fund. The link to the report can be found here:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/01/cdf-activity-update-Q2-2017-18.pdf</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:51:19 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872374

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people have accessed the Cancer Recovery Package in the last 12 months; and what proportion of those people had blood cancer.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134288
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>This information is not held centrally. NHS England is currently developing plans for national data collection.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 14:00:43 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872375

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 March 2018 to Question 132195, on Haematological Cancer: Mental Health Services, whether patients diagnosed with blood cancer but not yet starting treatment will be eligible for the Cancer Recovery Package.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134289
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>Every cancer patient will be eligible for the Recovery Package intervention regardless of their treatment status.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:57:20 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872376

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Nurses
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether every patient diagnosed with cancer receives support from a clinical nurse specialist; and if he will make a statement.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134290
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The Cancer Patient Experience Survey 2016 results show that 90% of respondents said that they were given the name of a clinical nurse specialist who would support them through their treatment. NHS England is working alongside Health Education England to expand the number of Clinical Nurse Specialists (CNS) and develop clear CNS competencies and routes into training. This will ensure every cancer patient has access to a CNS or other support worker by 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:56:27 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

872380

registered interest
date	26/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 19 March 2018 to Question 132100, on Haematological Cancer, whether he or NHS England plan to publish information on the work of multidisciplinary diagnostic centres before December 2018.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134294
answer	answer is ministerial correction date of answer 29/03/2018 answer text <p>The 10 multidisciplinary diagnostic centres or ‘rapid assessment and diagnostic centres’ have been described in the Progress Report on the cancer strategy published by NHS England in October 2017 at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2017/10/national-cancer-transformation-programme-2016-17-progress.pdf</a></p><p> </p><p>The evaluation of the centres is being undertaken by the Accelerate, Co-ordinate, Evaluate Partnership, which will publish its final report in December 2018.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 29/03/2018 13:55:02 answering member 4067 label Biography information for Steve Brine
tabling member	3960 label Biography information for Henry Smith

870191

registered interest
date	23/03/2018
answering body	Department for International Trade
answering dept id	202
answering dept short name	International Trade
answering dept sort name	International Trade
hansard heading	Developing Countries: Trade Agreements
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for International Trade, what assessment he has made of the potential effect of UK trade agreements with developing countries on the economies of those countries after the UK leaves the EU.
tabling member constituency	Crawley
tabling member printed	Henry Smith
uin	134061
answer	answer is ministerial correction date of answer 28/03/2018 answer text <p>Britain is an international leader on development, and the Department for International Trade is working with Department for International Development to ensure global prosperity is at the heart of our future trade policy.</p><p>We are committed to ensuring developing countries can use trade as an engine of poverty reduction, and trade agreements play an important role in this.</p><p>In 2016, the UK's total bilateral trade with countries that receive preferential access through unilateral preferences or Economic Partnership Agreements was £58bn.</p><p>Our first priority is to deliver continuity in our trading arrangements on leaving the EU.</p><p>In the future, the Government will also explore options to expand our relationships with developing countries.</p> answering member constituency Chelsea and Fulham answering member printed Greg Hands question first answered 28/03/2018 15:59:16 answering member 1526 label Biography information for Greg Hands
tabling member	3960 label Biography information for Henry Smith